We would love to hear your thoughts about our site and services, please take our survey here.
Never ever expected SP to be at this point, seems mad that anyone can get onboard and almost guarantee a 300% increase within 24month or maybe earlier? So much for the get in early to reap the rewards and the so called long term investment! Investors who have jumped in & out have made a fortune and the late arrivals to the party will see gains with little time invested. I see RNS’s being released all the time to bump up the SP, only for a fund raise soon after! FUM have done it in the past as well! Yet they can’t be bothered to release RNS’s now and can’t even give a decent financial forecast JOKE! Please someone buy these morons out discard the current BOD.
Think they need to get the male version over the line first & generate some returns for shareholders. They had several potential products like TPR100 pain relief, spent millions and told us all the commercial potential was massive, they were actually working on the final stages! Now just dropped it & thats fine but Eroxon still needs to prove itself in the biggest market of all, as does the Brand Eroxon! all those negative reviews need addressing as not being followed up with positives even now a year on! Something else they have no control over but need to do something about before extending the range.
It seems FUM have removed everything from their website but Eroxon / Med3000, no mention of dermasys technology either. Is this a plan for selling the company and then focusing on these other products as a separate entity?? A sexual health company with one product? Clearly they have been told that this is the way forward to attract investors & make the company more attractive. Seems strange to me as gone from a company with multiple potential products to one? As an investor this is less attractive to me! I suspect this is the case that the two names futura medical & Eroxon are intertwined and would need to be sold together, so the focusing on one product & sexual health is a focus on selling the business if the opportunity arises. IMO
Against my better judgment topped up, no bad news so why not all positive really so it’s hopefully a no brainer! If you listen to the presentation the CFO keeps on stating we can’t and won’t release the US launch date, as if they know when it will be? just reiterating the 12month from Feb that Haleon announced! Basically 10 month now, Jesus I’ve been here years and years forgot how many now, but 10 months is a drop in the ocean! I know I said I’d be out if no new announcements but Hey just can’t give up on the guaranteed payday coming very soon!
If this pulls back any further maybe us PI’s should club together and takeover? Barder should be worried with a SP this low as they are vulnerable to a hostile takeover!
FUM Valued £110m, they are expecting £5mill when sales start in US, then potential £45mill of sales milestones that they say are very easily achievable and how much are FUM royalties? A buyout seems inevitable! If Haleon bought them out they would save £50mill and take full royalties? At an initial cost of £300mill seems like a steal to me, and based on FUM staff levels could incorporate into current business and get shot of the dead wood guess who? Not needed!
A lot of these articles appear to be written by AI as little research done!
Barder states in presentation that they are not taking sales from products like viagra or Cialis, they are creating a new market with new customers. so if that’s the case why would these companies aggressively target Eroxon during launches to hamper sales?? They may have, when product was first released but based on this info would be a waste of money wouldn’t it? He just likes the words commercially sensitive, has to get those words in as many times as he can!😂
Disappointed but expected let’s face it, and Barder it’s not that you look miserable (from proactive video his words). It’s the cheesy smirk & the fact that when you speak we never get an answer just like a politician that we dislike DYOR! His likeness to a politician is unreal, when the company is bought out & he’s moved on, he has a calling!
Why have they not give an indication of revenue /sales forecast for 2024? We are now pretty much in all key EU markets as well as Saudi ( zero feedback on that one considering it is one of the most lucrative markets) and yet no forecast pathetic IMO! Get rid of that CFO who’s it is to forecast these things useless!
I expect a detailed plan of rollout execution across all approved markets including US, with an update on sales across all territories. An explanation as why they haven’t hit the 10 additional rollouts promised and a strategic plan for restarting other product R&D. I hope it’s not wishy washy BS we have already heard.
RNS states investor presentation as well as financial results! This is not the normal year on year results only! and can only assume that the BOD recognises that private investors are entitled to more information with a mention of answering investors submitted questions! I’m in hope of a positive outcome on the 10th otherwise I’m out!
I don’t think the BOD will have left themselves open to Haleon delays, they terminated the china deal because they hadn’t met deadlines, so same will apply with Haleon! Milestones must be being met, and as pointed out they have been caught out before so doubt they will let it happen again!
FUM have already declared they are achieving 20% market share, if this has been maintained since last update then surely this is a better indication of repeat sales? I would like % of ED market taken in other territories if we are looking at 20% across the board then happy days! you do the maths.
Bodes well that the 2 countries they have been selling in for 12month, Eroxon has won awards! Don’t see why this won’t continue into all countries! I would also like to see FUM pick back up where they left off with the other potential products or least a timeline to when that will be! What would the SP have been if they’d had the funds & the R&D had continued??? If the company was sold what are these products worth??
10th April will be the turning point for this Share! With hopefully a clear focus on financials & a detailed plan for the next 12month with profit forecasts, USA timescales to market & ROTW! If not & the BOD give nothing away SP will plummet IMO!
Anybody any idea? I’m only aware of the Boots product if the year!
“Eroxon has been nominated for a number of healthcare industry awards and has won two to-date.”
Well what do you expect? Still very little news flow and people are becoming impatient! FUM have clearly decided not release RNS’s voluntarily and perhaps in JB ‘s case for good reason as he only caused the SP to plummet. But news is coming & when it comes I’m expecting lots of it, not just a yearly update but informative news that will hopefully push the SP upwards!
I suspect FUM will be bought out once they have completed the Donkey work and Eroxon US date is set! People forget FUM have multiple products under R&D and TPR100 was very near commercialisation which again could be a ground breaking product more effective than market leading topical diclofenac with only 20% active ingredient! This focus on one product although essential has also removed SP value IMO! So FUM valuation once these other products are reevaluated plus Eroxon who knows, but how long can FUM ignore its R&D roots??
When results were issued last year there was a video which mentioned future revenue in 2025 when US sales take off with a prediction of £400 million. Work it out everyone it dosnt take Einstein to work out the possible SP and to be honest FUM aren’t great at blowing their own trumpet so this figure will be on the pessimistic side if anything. IMO £1billion valuation is somewhere near for just Eroxon alone, we also have to consider the possible value of the products put on hold to focus on Eroxon.